NEW YORK (GenomeWeb) – The Worldwide Innovative Networking Consortium in personalized cancer medicine today announced the approval of six new members.
The new members are Asan Medical Center in South Korea; Cambridge Cancer Center in the UK; Cancer Research UK; CEO Roundtable on Cancer, headquartered in Cary, NC; the Kimmel Cancer Center at Jefferson in Philadelphia; and Memorial Sloan Kettering Cancer Center in New York.
The WIN Consortium now has 39 member organizations who share a goal of rapidly translating personalized cancer medicine into standards for clinical care. The members share information and conduct multi-institutional, global clinical trials, and research to discover and validate advances in genomic and biomarker-based cancer medicine.
In a statement, Asan Cancer Centre Director Chang Sik Yu said that membership into the consortium "will provide us with the opportunity to promote ground-breaking global clinical trials with other leading organizations to advance personalized cancer medicine. With this opportunity, we hope to make an important contribution to this worldwide effort to overcome cancer."